{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:01:07Z","timestamp":1792195267719,"version":"4.4.0"},"reference-count":132,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:p>Laboratory diagnosis of Ebola virus disease plays a critical role in outbreak response efforts; however, establishing safe and expeditious testing strategies for this high-biosafety-level pathogen in resource-poor environments remains extremely challenging. Since the discovery of Ebola virus in 1976 via traditional viral culture techniques and electron microscopy, diagnostic methodologies have trended toward faster, more accurate molecular assays. Importantly, technological advances have been paired with increasing efforts to support decentralized diagnostic testing capacity that can be deployed at or near the point of patient care. The unprecedented scope of the 2014-2015 West Africa Ebola epidemic spurred tremendous innovation in this arena, and a variety of new diagnostic platforms that have the potential both to immediately improve ongoing surveillance efforts in West Africa and to transform future outbreak responses have reached the field. In this review, we describe the evolution of Ebola virus disease diagnostic testing and efforts to deploy field diagnostic laboratories in prior outbreaks. We then explore the diagnostic challenges pervading the 2014-2015 epidemic and provide a comprehensive examination of novel diagnostic tests that are likely to address some of these challenges moving forward.<\/jats:p>","DOI":"10.1128\/cmr.00003-16","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T02:37:01Z","timestamp":1468463821000},"page":"773-793","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":196,"title":["Diagnosis of Ebola Virus Disease: Past, Present, and Future"],"prefix":"10.1128","volume":"29","author":[{"given":"M. Jana","family":"Broadhurst","sequence":"first","affiliation":[{"name":"Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J. G.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Public Health England, Porton Down, Salisbury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nira R.","family":"Pollock","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1128\/9781555815905.ch87","volume-title":"Manual of molecular and clinical laboratory immunology","author":"Strong JE","year":"2006","unstructured":"Strong JE , Grolla A , Jahrling PB , Feldmann H . 2006. Filoviruses and arenaviruses, p 774\u2013790. In Detrick B , Hamilton RG , Folds JD (ed), Manual of molecular and clinical laboratory immunology, 7th ed. ASM Press, Washington, DC.","edition":"7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.8.4330-4341.2004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir299"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411680"},{"key":"e_1_3_2_6_2","first-page":"923","volume-title":"Fields virology","author":"Feldmann H","year":"2013","unstructured":"Feldmann H , Sanchez A , Geisbert TW . 2013. Filoviridae: Marburg and Ebola viruses, p 923\u2013962. In Knipe EM , Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"6"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90719-X"},{"key":"e_1_3_2_8_2","first-page":"247","article-title":"Ebola hemorrhagic fever in Sudan, 1976","volume":"56","author":"WHO International Study Team","year":"1978","unstructured":"WHO International Study Team. 1978. Ebola hemorrhagic fever in Sudan, 1976. Bull World Health Organ 56:247\u2013270.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_2_9_2","first-page":"429","article-title":"Indirect immunofluorescence for the diagnosis of Lassa fever infection","volume":"52","author":"Wulff H","year":"1975","unstructured":"Wulff H , Lange J . 1975. Indirect immunofluorescence for the diagnosis of Lassa fever infection. Bull World Health Organ 52:429\u2013436.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/514313"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/514321"},{"key":"e_1_3_2_12_2","first-page":"205","article-title":"Laboratory diagnosis of Ebola and Marburg hemorrhagic fever","volume":"98","author":"Grolla A","year":"2005","unstructured":"Grolla A , Lucht A , Dick D , Strong JE , Feldmann H . 2005. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull Soc Pathol Exot 98:205\u2013209.","journal-title":"Bull Soc Pathol Exot"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83162"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.444-451.2006"},{"key":"e_1_3_2_15_2","volume-title":"Zaire-Ebola virus nucleoprotein (EBOV-NP) IgG (AE-320520-1) kit and IgM (AE-320530-1) ELISA kit product descriptions","author":"Alpha Diagnostic International","year":"2016","unstructured":"Alpha Diagnostic International. 2016. Zaire-Ebola virus nucleoprotein (EBOV-NP) IgG (AE-320520-1) kit and IgM (AE-320530-1) ELISA kit product descriptions. Alpha Diagnostics International, Inc., San Antonio, TX."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504874"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001175"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/514318"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/7422"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02405-3"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090402"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.30.4.947-950.1992"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.9.3267-3271.2001"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(03)00131-9"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-003-0204-z"},{"key":"e_1_3_2_26_2","first-page":"124","article-title":"Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014","volume":"72","author":"Reusken C","year":"2014","unstructured":"Reusken C , Niedrig M , Pas S , Anda P , Baize S , Charrel R , Di Caro A , Drosten C , Fernandez-Garcia MD , Franco L , Gunther S , Leparc-Goffart I , Martina B , Pannetier D , Papa A , Sanchez-Seco MP , Vapalahti L , Koopmans M . 2014. Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014. J Clin Virol 72:124\u2013134.","journal-title":"J Clin Virol"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/514282"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(200004)60:4<463::AID-JMV15>3.0.CO;2-M"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/514291"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/503836"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000212"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.11.4125-4130.2001"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.7.2323-2330.2002"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2202.151250"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv304"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83111"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.10.021"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv187"},{"key":"e_1_3_2_39_2","unstructured":"World Health Organization. 2014. Laboratory diagnosis of Ebola virus disease. World Health Organization Geneva Switzerland. http:\/\/apps.who.int\/iris\/bitstream\/10665\/134009\/1\/WHO_EVD_GUIDANCE_LAB_14.1_eng.pdf ."},{"key":"e_1_3_2_40_2","unstructured":"Centers for Disease Control and Prevention. 2015. Guidance for collection transport and submission of specimens for Ebola virus testing. http:\/\/www.cdc.gov\/vhf\/ebola\/healthcare-us\/laboratories\/specimens.html ."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.01.017"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.4.1753-1755.2004"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/513145a"},{"key":"e_1_3_2_44_2","volume-title":"Manual for the care and management of patients in Ebola care units\/community care centers; interim emergency guidance","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Manual for the care and management of patients in Ebola care units\/community care centers; interim emergency guidance. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2015.20.44.30055"},{"key":"e_1_3_2_46_2","first-page":"41","article-title":"Outbreak of Ebola haemorrhagic fever, Uganda, August 2000-January 2001","volume":"76","author":"World Health Organization","year":"2001","unstructured":"World Health Organization. 2001. Outbreak of Ebola haemorrhagic fever, Uganda, August 2000-January 2001. Wkl Epidemiol Rec 76:41\u201346.","journal-title":"Wkl Epidemiol Rec"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1863-2378.2012.01477.x"},{"key":"e_1_3_2_48_2","unstructured":"Centers for Disease Control and Prevention. 2016. Ebola outbreaks 2000-2014. Centers for Disease Control and Prevention Atlanta GA. http:\/\/www.cdc.gov\/vhf\/ebola\/outbreaks\/history\/summaries.html ."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001183"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404505"},{"key":"e_1_3_2_51_2","unstructured":"World Health Organization. 2015. Emergency guidance selection and use of Ebola in vitro diagnostic (IVD) assays. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/csr\/resources\/publications\/ebola\/ivd-assays\/en\/ ."},{"key":"e_1_3_2_52_2","unstructured":"World Health Organization. 2014. Emergency use assessment and listing (EUAL) procedure for Ebola virus disease. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/purchasing\/en\/ ."},{"key":"e_1_3_2_53_2","unstructured":"World Health Organization. 2014. Target product profile for Zaire Ebolavirus rapid simple test to be used in the control of the Ebola outbreak in West Africa. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/medicines\/publications\/target-product-profile.pdf ."},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3215"},{"key":"e_1_3_2_55_2","volume-title":"Guidance for U.S. laboratories for managing and testing routine clinical specimens when there is a concern about Ebola virus disease","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention. 2015. Guidance for U.S. laboratories for managing and testing routine clinical specimens when there is a concern about Ebola virus disease. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/vhf\/ebola\/healthcare-us\/laboratories\/safe-specimen-management.html ."},{"key":"e_1_3_2_56_2","unstructured":"Centers for Disease Control and Prevention USDA. 2014. Select agents and toxins list Federal Select Agent Program. U.S. Department of Health and Human Services Washington DC. http:\/\/www.selectagents.gov\/SelectAgentsandToxinsList.html ."},{"key":"e_1_3_2_57_2","unstructured":"Centers for Disease Control and Prevention. 19 November 2014. Interim guidance regarding compliance with select agent regulations for laboratories handling patient specimens that are known or suspected to contain Ebola virus. Centers for Disease Control and Prevention Atlanta GA. http:\/\/www.cdc.gov\/vhf\/ebola\/healthcare-us\/laboratories\/select-agent-regulations.html ."},{"key":"e_1_3_2_58_2","volume-title":"Management of hazard group 4 viral haemorrhagic fevers and similar human infectious diseases of high consequence","author":"Department of Health UK, Advisory Committee on Dangerous Pathogens","year":"2015","unstructured":"Department of Health UK, Advisory Committee on Dangerous Pathogens. 2015. Management of hazard group 4 viral haemorrhagic fevers and similar human infectious diseases of high consequence. Public Health England, London, England. https:\/\/www.gov.uk\/government\/publications\/viral-haemorrhagic-fever-algorithm-and-guidance-on-management-of-patients ."},{"key":"e_1_3_2_59_2","volume-title":"Interim guidance on the use of rapid Ebola antigen detection tests","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Interim guidance on the use of rapid Ebola antigen detection tests. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/csr\/resources\/publications\/ebola\/ebola-antigen-detection\/en\/ ."},{"key":"e_1_3_2_60_2","volume-title":"Emergency use assessment and listing for Ebola virus disease IVDs, public report, product: RealStar filovirus screen RT-PCR kit 1.0","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. Emergency use assessment and listing for Ebola virus disease IVDs, public report, product: RealStar filovirus screen RT-PCR kit 1.0. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/purchasing\/en\/ ."},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.04.001"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61042-X"},{"key":"e_1_3_2_63_2","volume-title":"Emergency use authorization, RealStar Ebolavirus RT-PCR kit 1.0; letter of authorization","author":"U.S. Food and Drug Administration","year":"2014","unstructured":"U.S. Food and Drug Administration. 2014. Emergency use authorization, RealStar Ebolavirus RT-PCR kit 1.0; letter of authorization. U.S. Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_64_2","volume-title":"Emergency use assessment and listing for Ebola virus disease IVDs, public report, product: Liferiver Ebola virus (EBOV) real time RT-PCR kit","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Emergency use assessment and listing for Ebola virus disease IVDs, public report, product: Liferiver Ebola virus (EBOV) real time RT-PCR kit. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/purchasing\/en\/ ."},{"key":"e_1_3_2_65_2","volume-title":"Emergency use authorization, CDC Ebola virus NP real-time RT-PCR assay; letter of authorization","author":"U.S. Food and Drug Administration","year":"2015","unstructured":"U.S. Food and Drug Administration. 2015. Emergency use authorization, CDC Ebola virus NP real-time RT-PCR assay; letter of authorization. U.S. Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_66_2","volume-title":"Emergency use authorization, CDC Ebola virus VP40 real-time RT-PCR assay; letter of authorization","author":"U.S. Food and Drug Administration","year":"2015","unstructured":"U.S. Food and Drug Administration. 2015. Emergency use authorization, CDC Ebola virus VP40 real-time RT-PCR assay; letter of authorization. U.S. Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_67_2","volume-title":"Emergency use authorization, DoD EZ1 real-time RT-PCR assay; letter of authorization","author":"U.S. Food and Drug Administration","year":"2014","unstructured":"U.S. Food and Drug Administration. 2014. Emergency use authorization, DoD EZ1 real-time RT-PCR assay; letter of authorization. U.S. Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_68_2","volume-title":"Emergency use authorization, LightMix Ebola Zaire rRT-PCR test; letter of authorization","author":"U.S. Food and Drug Administration","year":"2014","unstructured":"U.S. Food and Drug Administration. 2014. Emergency use authorization, LightMix Ebola Zaire rRT-PCR test; letter of authorization. U.S. Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv361"},{"key":"e_1_3_2_70_2","volume-title":"Emergency use assessment and listing for Ebola virus disease IVDs, public report, product: Xpert Ebola assay","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Emergency use assessment and listing for Ebola virus disease IVDs, public report, product: Xpert Ebola assay. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/purchasing\/en\/ ."},{"key":"e_1_3_2_71_2","volume-title":"Emergency use authorization, Xpert Ebola assay; letter of authorization","author":"U.S. Food and Drug Administration","year":"2015","unstructured":"U.S. Food and Drug Administration. 2015. Emergency use authorization, Xpert Ebola assay; letter of authorization. U.S. ood and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142216"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02724-15"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001980"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0636"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2202.151238"},{"key":"e_1_3_2_77_2","unstructured":"U.S. Food and Drug Administration. 2014. Emergency use authorization FilmArray Biothreat-E test; letter of authorization. U.S. Food and Drug Administration Rockville MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_78_2","unstructured":"World Health Organization. 2015. Emergency use assessment and listing for Ebola virus disease IVDs public report product: FilmArray Biothreat-E. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/purchasing\/en\/ ."},{"key":"e_1_3_2_79_2","unstructured":"U.S. Food and Drug Administration. 2015. Emergency use authorization FilmArray NGDS BT-E assay; letter of authorization. U.S. Food and Drug Administration Rockville MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02287-15"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01317-15"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00527-15"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid.ofv133.106"},{"key":"e_1_3_2_84_2","volume-title":"Emergency use authorization, ReEBOV antigen rapid test; letter of authorization","author":"U.S. Food and Drug Administration","year":"2015","unstructured":"U.S. Food and Drug Administration. 2015. Emergency use authorization, ReEBOV antigen rapid test; letter of authorization. U.S. Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_85_2","volume-title":"Emergency use assessment and listing for Ebola virus disease IVDs, public report, product: ReEBOV antigen rapid test kit","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Emergency use assessment and listing for Ebola virus disease IVDs, public report, product: ReEBOV antigen rapid test kit. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/purchasing\/en\/ ."},{"key":"e_1_3_2_86_2","volume-title":"Emergency use authorization, OraQuick Ebola rapid antigen test; letter of authorization","author":"U.S. Food and Drug Administration","year":"2015","unstructured":"U.S. Food and Drug Administration. 2015. Emergency use authorization, OraQuick Ebola rapid antigen test; letter of authorization. U.S. Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_87_2","volume-title":"Emergency use authorization, OraQuick Ebola rapid antigen test; letter of authorization","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. 2016. Emergency use authorization, OraQuick Ebola rapid antigen test; letter of authorization. U.S. Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/MedicalDevices\/Safety\/EmergencySituations\/ucm161496.htm#ebola ."},{"key":"e_1_3_2_88_2","unstructured":"World Health Organization. 2016. Emergency use assessment and listing for Ebola virus disease IVDs; public report; product: OraQuick Ebola rapid antigen test kit (cadaveric oral fluid and whole blood). World Health Organization Geneva Switzerland. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/purchasing\/en\/ ."},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6512a4"},{"key":"e_1_3_2_90_2","unstructured":"World Health Organization. 2015. Emergency use assessment and listing for Ebola virus disease IVDs public report product: SD Q Line Ebola Zaire Ag. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/purchasing\/en\/ ."},{"key":"e_1_3_2_91_2","unstructured":"World Health Organization. 2014. Laboratory: how to safely collect blood samples from persons suspected to be infected with highly infectious blood-borne pathogens (e.g. Ebola). World Health Organization Geneva Switzerland. http:\/\/who.int\/csr\/resources\/publications\/ebola\/blood-collect-en.pdf ."},{"key":"e_1_3_2_92_2","unstructured":"World Health Organization. 2014. How to safely collect oral swabs (saliva) from deceased patients suspected to be infected with Ebola; interim guideline. World Health Organization Geneva Switzerland. http:\/\/who.int\/csr\/resources\/publications\/ebola\/safely-collect-oral-swabs\/en.pdf ."},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92102-X"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.16.4.704-708.1982"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.20.3.486-489.1984"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01449-15"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2004.03.015"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1086\/520601"},{"key":"e_1_3_2_99_2","volume-title":"hospitals","author":"Centers for Disease Control and Prevention","year":"2005","unstructured":"Centers for Disease Control and Prevention. 2005. Interim guidance for managing patients with suspected viral hemorrhagic fever in U.S. hospitals. Centers for Disease Control and Prevention, Atlanta, GA."},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00165-15"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1086\/314524"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02960-15"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1258\/0004563001899997"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00144-9"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268816000054"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008859"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6086.541"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200001000-00041"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1086\/520545"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511410"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30060-3"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1512928"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509773"},{"key":"e_1_3_2_114_2","unstructured":"World Health Organization. 2015. Criteria for declaring the end of the Ebola outbreak in Guinea Liberia or Sierra Leone. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/csr\/disease\/ebola\/declaration-ebola-end\/en\/ ."},{"key":"e_1_3_2_115_2","unstructured":"World Health Organization. 2016. Clinical care for survivors of Ebola virus disease; interim guidance; updated April 2016. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/csr\/resources\/publications\/ebola\/guidance-survivors\/en\/ ."},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv454"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411677"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500306"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00180-0"},{"key":"e_1_3_2_120_2","doi-asserted-by":"crossref","unstructured":"Baggi FM Taybi A Kurth A Van Herp M Di Caro A Wolfel R Gunther S Decroo T Declerch H Jonckheere \u00a0 . 2014. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea June 2014. Euro Surveill 19:pii=20983. http:\/\/dx.doi.org\/10.2807\/1560-7917.ES2014.19.49.20983.","DOI":"10.2807\/1560-7917.ES2014.19.49.20983"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2202.151796"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1259657"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14490"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.06.007"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14594"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2107.150522"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0220-9"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature16041"},{"key":"e_1_3_2_129_2","doi-asserted-by":"crossref","unstructured":"Walker NF Brown CS Youkee D Baker P Williams N Kalawa A Russell K Samba AF Bentley N Koroma F King MB Parker BE Thompson M Boyles T Healey B Kargbo B Bash-Taqi D Simpson AJ Kamara A Kamara TB Lado M Johnson O Brooks T . 2015. Evaluation of a point-of-care blood test for identification of Ebola virus disease at Ebola holding units Western Area Sierra Leone January to February 2015. Euro Surveill 20:pii=21073. http:\/\/dx.doi.org\/10.2807\/1560-7917.ES2015.20.12.21073.","DOI":"10.2807\/1560-7917.ES2015.20.12.21073"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.3390\/s150408605"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1039\/c5lc00055f"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004472"},{"key":"e_1_3_2_133_2","unstructured":"World Health Organization. 2016. WHO Ebola situation report 30 March 2016. World Health Organization Geneva Switzerland. http:\/\/apps.who.int\/ebola\/current-situation\/ebola-situation-report-30-march-2016 ."}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00003-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00003-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T22:26:49Z","timestamp":1656800809000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.00003-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1128\/CMR.00003-16"],"URL":"https:\/\/doi.org\/10.1128\/cmr.00003-16","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"2016-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}